{\rtf1\ansi\ansicpg1252\uc1\deff0\stshfdbch0\stshfloch0\stshfhich0\stshfbi0\deflang1033\deflangfe1033{\fonttbl{\f0\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f37\froman\fcharset0\fprq0{\*\panose 00000000000000000000}ABIFG M+ Melior{\*\falt Melior};}{\f38\froman\fcharset0\fprq0{\*\panose 00000000000000000000}ABIFJ N+ Melior{\*\falt Melior};}{\f189\froman\fcharset238\fprq2 Times New Roman CE;}
{\f190\froman\fcharset204\fprq2 Times New Roman Cyr;}{\f192\froman\fcharset161\fprq2 Times New Roman Greek;}{\f193\froman\fcharset162\fprq2 Times New Roman Tur;}{\f194\froman\fcharset177\fprq2 Times New Roman (Hebrew);}
{\f195\froman\fcharset178\fprq2 Times New Roman (Arabic);}{\f196\froman\fcharset186\fprq2 Times New Roman Baltic;}{\f197\froman\fcharset163\fprq2 Times New Roman (Vietnamese);}}{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;
\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;
\red128\green128\blue128;\red192\green192\blue192;}{\stylesheet{\ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext0 Normal;}{\*\cs10 \additive \ssemihidden 
Default Paragraph Font;}{\*\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\trcbpat1\trcfpat1\tscellwidthfts0\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv 
\ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \fs20\lang1024\langfe1024\cgrid\langnp1024\langfenp1024 \snext11 \ssemihidden Normal Table;}{\s15\ql \li0\ri0\nowidctlpar\faauto\rin0\lin0\itap0 
\f37\fs24\cf1\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext15 Default;}{\s16\ql \li0\ri0\sl200\slmult0\nowidctlpar\faauto\rin0\lin0\itap0 \f37\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \sbasedon15 \snext15 CM1;}{
\s17\ql \li0\ri0\sl200\slmult0\nowidctlpar\faauto\rin0\lin0\itap0 \f37\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \sbasedon15 \snext15 CM2;}{\s18\ql \li0\ri0\sa98\nowidctlpar\faauto\rin0\lin0\itap0 
\f37\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \sbasedon15 \snext15 CM4;}{\s19\ql \li0\ri0\sl198\slmult0\nowidctlpar\faauto\rin0\lin0\itap0 \f37\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \sbasedon15 \snext15 CM3;}{
\s20\ql \li0\ri0\sa160\nowidctlpar\faauto\rin0\lin0\itap0 \f37\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \sbasedon15 \snext15 CM5;}}{\*\latentstyles\lsdstimax156\lsdlockeddef0}{\*\rsidtbl \rsid6045737}{\*\generator Microsoft Word 11.0.6568;}
{\info{\title Document}{\subject Extracted Pages}{\author U.S. Government Printing Office}{\operator College of DuPage}{\creatim\yr2005\mo6\dy28\hr1\min35}{\revtim\yr2006\mo5\dy29\hr13\min30}{\version2}{\edmins3}{\nofpages1}{\nofwords595}{\nofchars3397}
{\*\company COD}{\nofcharsws3985}{\vern24579}}\margl460\margr660\margt620\margb320 \widowctrl\ftnbj\aenddoc\noxlattoyen\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\hyphcaps0\horzdoc\dghspace120\dgvspace120\dghorigin1701\dgvorigin1984\dghshow0\dgvshow3
\jcompress\viewkind1\viewscale100\nolnhtadjtbl\rsidroot6045737 \fet0\sectd \sbknone\linex0\sectdefaultcl\sftnbj {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2\pnucltr\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl3
\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}
{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}\pard\plain 
\s15\qc \li0\ri0\sa300\nowidctlpar\faauto\rin0\lin0\itap0 \f37\fs24\cf1\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\b\cf6\insrsid6045737\charrsid6045737 Federal Register }{\b\f38\cf6\insrsid6045737\charrsid6045737 
/ Vol. 70, No. 123 / Tuesday, June 28, 2005 / Notices 
\par }\pard\plain \s16\ql \li0\ri63\sl200\slmult0\nowidctlpar\faauto\rin63\lin0\itap0 \f37\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\f38\cf1\insrsid6045737\charrsid6045737 \lquote \lquote 
Gingivitis: Development and Evaluation of Drugs for Treatment or Prevention.\rquote \rquote  This guidance is intended to assist sponsors in developing clinical trials for drug products that treat or prevent gingivitis. 
\par }\pard\plain \s17\ql \fi180\li0\ri0\sl200\slmult0\nowidctlpar\faauto\rin0\lin0\itap0 \f37\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\f38\cf1\insrsid6045737\charrsid6045737 Gingivitis, an inflammation of the soft tissues t
hat surround the teeth, is a part of the wider classification of periodontal diseases, which include gingivitis at the milder end and periodontitis at the more severe end. In 1986, FDA approved Peridex (0.12% chlorhexidine gluconate rinse), the first pres
cription product for gingivitis. In 1997, Colgate\rquote 
s Total toothpaste (0.30% triclosan, 0.24% sodium fluoride) was approved through the new drug application (NDA) process as an over-the-counter (OTC) dentifrice that also has a gingivitis indication. During t
he past several decades, many products have also entered the marketplace as OTC products that were purported to treat or prevent gingivitis. As a result of the proliferation and promotion of those products, the agency convened a subcommittee of the Dental
 Products Panel (the Subcommittee) in 1993 to evaluate OTC products that make gingivitis and related claims and that were in the marketplace without an NDA. The Subcommittee\rquote 
s charge was to review the submitted data and to report its findings on the safety and effectiveness of OTC ingredients for the reduction or prevention of gingivitis}{\f38\cf6\insrsid6045737\charrsid6045737 . }{\b\f38\cf6\insrsid6045737\charrsid6045737 
On May 29, 2003, a final subcommittee report was published in the }{\b\cf6\insrsid6045737\charrsid6045737 Federal Register }{\b\f38\cf6\insrsid6045737\charrsid6045737 
(68 FR 32232) as an advance notice of proposed rulemaking, the first step in establishing an OTC monograph for these drug products.}{\b\f38\cf1\insrsid6045737\charrsid6045737  
\par }{\f38\cf1\insrsid6045737\charrsid6045737 Unlike the NDA process that consists of a review of the entire drug product, the monograph process reviews only active ingredients in the class of drug products for safety and efficacy. }{
\b\f38\cf6\insrsid6045737\charrsid6045737 Until the monograph is fin
alized, only gingivitis products containing active ingredients that were marketed in the United States before 1975 can continue to be marketed. Any manufacturer attempting to enter the marketplace with a gingivitis product containing an active ingredient 
that has no prior marketing history in the United States should either petition the developing monograph to consider its inclusion or submit a new NDA for approval before marketing.}{\f38\cf1\insrsid6045737\charrsid6045737 
 Sponsors of OTC antigingivitis drugs with active ingredients that the Subco
mmittee classified as needing further information to make a decision are encouraged to submit further data for review. As a result of these actions, FDA is publishing this guidance document on the development of antigingivitis drugs. 
\par }\pard\plain \s15\ql \li0\ri140\sl200\slmult0\nowidctlpar\faauto\rin140\lin0\itap0 \f37\fs24\cf1\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\f38\insrsid6045737\charrsid6045737 The guidance is inten
ded to aid drug sponsors in developing clinical trials either for submitting additional information to the antigingivitis rulemaking, or for gaining approval for a new antigingivitis drug through the NDA process. 
\par }\pard\plain \s17\ql \fi180\li0\ri0\sl200\slmult0\nowidctlpar\faauto\rin0\lin0\itap0 \f37\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\f38\cf1\insrsid6045737\charrsid6045737 This guidance document provides assistance
 in several ways. It addresses specific design elements such as choosing inclusionary and exclusionary criteria, selecting relevant endpoints, assessing gingivitis, determining the clinical significance of the effect, and collecting meaningful safety data
.
 It also provides comments on general concerns (e.g., prevention versus treatment claims, OTC versus prescription status, special population enrollment, and nonclinical development issues related to products that are intended for administration within the
 oral cavity for the treatment or prevention of gingivitis). 
\par }\pard\plain \s15\ql \li0\ri0\nowidctlpar\faauto\rin0\lin0\itap0 \f37\fs24\cf1\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\f38\insrsid6045737\charrsid6045737 This draft guidance is being issued consistent with FDA\rquote 
s good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the agency\rquote s current thinking on t
he development and evaluation of drugs for treatment or prevention of gingivitis. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies t
he requirements of the applicable statutes and regulations. }{\cf0\insrsid6045737\charrsid6045737 
\par }\pard\plain \s19\ql \li0\ri0\sl198\slmult0\nowidctlpar\faauto\rin0\lin0\itap0 \f37\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\f38\insrsid6045737\charrsid6045737 August 31, 2005. 
\par }}